RGNT

Regentis Biomaterials Ltd

2.04

Jul 21 • 03:59PM ET +0.04 (2.00%)

2.00

Aftermarket • 07:34PM ET -0.04 (-1.93%)

Healthcare Medical Instruments & Supplies Israel Nano AMEX

Jul 20, 9:35 AMJapan Patent Office issues Notice of Allowance for Regentis patent on solvent-free GelrinC process and liquid formulation

Peers: BNGO LUCY NXGL RVP ZJYL FEMY GCTK CUPR HBIO MLSS

Scroll to Statements

Index	-
Market Cap	14.33M
Enterprise Value	8.15M
Income	-13.67M
Sales	0.00M
Book/sh	0.92
Cash/sh	1.05
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	10
IPO	Dec 04, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.23
P/C	1.94
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.65
Current Ratio	2.65
Debt/Eq	0.25
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-2.67
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	11.45% -71.58%
Sales past 3/5Y	- -
EPS Y/Y TTM	-376.99%
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	52.02%
Insider Trans	0.00%
Inst Own	12.08%
Inst Trans	-0.49%
ROA	-336.99%
ROE	-
ROIC	-287.69%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-40.01%
SMA50	-29.56%
SMA200	-50.52%
Trades

Shs Outstand	4.93M
Shs Float	3.37M
Short Float	4.24%
Short Ratio	0.03
Short Interest	0.14M
52W High	15.50 -86.84%
52W Low	1.23 65.64%
Volatility	21.77% 16.04%
ATR (14)	0.75
RSI (14)	39.93
Beta	-
Rel Volume	0.03
Avg Volume	5.39M
Volume	188,372

Perf Week	-19.69%
Perf Month	-52.45%
Perf Quarter	-31.15%
Perf Half Y	-71.27%
Perf YTD	-69.73%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	10.00
Prev Close	2.00
Price	2.04
Change	2.00%

Jul-20-26 09:00AM	Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology (ACCESSWIRE) -15.97%
Jul-16-26 11:30AM	Regentis Biomaterials (RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process (NewMediaWire) -8.64%
Jul-15-26 09:00AM	Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch (ACCESSWIRE)
Jun-17-26 09:05PM	Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement (ACCESSWIRE) -22.13% -9.68%
Jun-15-26 02:06PM	Why Did RGNT Stock Surge More Than 850% Today? (Stocktwits) +526.67%
03:30PM	Loading…
Jun-08-26 03:30PM	Regentis Biomaterials (RGNT) Advances European Commercial Launch Plans for GelrinC (NewMediaWire)
08:32AM	Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate (ACCESSWIRE)
Jun-01-26 03:15PM	Regentis Biomaterials (RGNT) Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones (NewMediaWire) -11.89%
May-29-26 03:15PM	Regentis Biomaterials (RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant (NewMediaWire) -6.57%
May-28-26 03:30PM	Regentis Biomaterials (RGNT) Is 'One to Watch' (NewMediaWire)
May-26-26 03:40PM	Regentis Biomaterials (RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair (NewMediaWire)
Apr-16-26 08:30AM	Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon (ACCESSWIRE)
Mar-17-26 08:30AM	Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400% (ACCESSWIRE) +5.88%
Feb-24-26 04:15PM	Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update (ACCESSWIRE) +8.11%
01:11PM	Regentis Biomaterials (RGNT) Appoints New CFO/CBO as GelrinC Nears Commercial Launch (Insider Monkey)
08:30AM	Loading…
Feb-19-26 08:30AM	Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair (ACCESSWIRE)
Feb-17-26 08:30AM	Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs (ACCESSWIRE) -10.47%
Feb-04-26 08:33AM	Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial (ACCESSWIRE)
Jan-29-26 08:33AM	Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S. (ACCESSWIRE)
Jan-20-26 08:33AM	Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method (ACCESSWIRE)
Jan-06-26 08:21AM	Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation (ACCESSWIRE)
Dec-18-25 08:35AM	Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC (ACCESSWIRE)
Dec-05-25 04:10PM	Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering (GlobeNewswire)
Dec-03-25 07:23PM	Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering (GlobeNewswire)

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

CEO & Executive ChairmanDr. Ehud Geller Ph.D.

Co-Founder & Chief Scientific OfficerDr. Dror Seliktar Ph.D.

CFO & Chief Business OfficerMr. Ori Gon

Chief Medical OfficerDr. Galit Reske Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGNT

Regentis Biomaterials Ltd

Upgrade your Finviz experience